| Predicate |
Object |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-41
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-735
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-75 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-635
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P5-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-10 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12R1-19 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P5-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N1-21
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-09
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P19-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12P21-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-575
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-635
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-00 |
| filingDate |
1992-06-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate |
1993-10-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
JP-H05271279-A |
| titleOfInvention |
Human parathyroid hormone mutein and process for its production |
| abstract |
(57) [Summary] [Object] To provide a novel derivative of human thyroid hormone (human PTH), which is useful as a drug. [Structure] An agonist derivative in which the methionine residues at positions 8 and 18 of human PTH are replaced with other amino acids, an agonist derivative in which one amino acid residue at positions 34 to 47 is replaced with cysteine, and an N-terminal amino acid sequence are shown. 3 to 6 The residue-deficient antagonist derivatives were respectively obtained by recombinant gene method. [Effect] By converting the methionine group into another fat-soluble amino acid residue, a human PTH derivative stable against oxidation action can be obtained, and a PTH antagonist derivative can be obtained by deleting the N-terminal amino acid. A human PTH derivative that can be converted into a more excellent compound by forming a dimer or introducing another functional group by converting into cysteine was provided. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-112218881-A |
| priorityDate |
1991-08-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |